News Release
For immediate release
GliSODin®
Shown to Inhibit Surgery-Related Cellular DNA Damage in the
journal Intensive Care Medicine
MORRISTOWN,
NJ (March 12, 2005) PL Thomas (PLT) today, in association with
Isocell, Paris, France, announced the results of a new study
using their exclusive dietary supplement ingredient, GliSODin®
in the journal of
Intensive Care Medicine1. GliSODin
supplementation prior to an invasive surgical procedure was
shown to significantly inhibit several measures of cellular
damage, including DNA damage and protection of spinal cord
tissues, without negative effects or impairing organ function.
The
researchers were positive in their findings, stating that in
this study the use of GliSODin “may thus be an
adjunctive measure for elective surgery and / or used as
nutritional support under conditions of prolonged period of
enhanced oxidative stress.”
Invasive
surgery interrupts and reintroduces blood flow to tissues
causing cellular and tissue damage by reactive oxygen species (ROS).
This is called ischemia-reperfusion injury, and the most
vulnerable organs are the spinal cord and kidneys. If the
cellular DNA and membrane can be protected from ROS, the tissues
and organs may be significantly protected and will suffer less
damage.
In the
study, conducted at the University of Ulm, invasive surgery was
modeled by clamping the thoracic aorta for 30 minutes under
carefully controlled conditions. GliSODin supplementation for
14 days prior to the procedure was compared to similar
supplementation with placebo.
GliSODin was
shown to significantly reduce surgery- and Ischemia/repurfusion-related
DNA damage and decrease spinal cord cell death. Further,
cellular damage typically seen during surgery considered harmful
to cardiac function was inhibited (venous acidosis) without
limiting normal lipid peroxidation or organ function. No
protective benefit was shown in the placebo group.
This new
study builds upon previous research in humans. In a
double-blind, placebo-controlled clinical trial that was
published in
Free Radical Research2, September 2004, the
researchers showed GliSODin supplementation protects cellular
DNA against induced oxidative damage. GliSODin was the only
supplement to show a protective benefit in this well established
model of oxidative stress.
In the new
study, swine were chosen for the tests as issues that can
influence human studies, such as smoking, dietary habits or
exercise are negated. Also, swine are similar to humans in
susceptibility to oxidative stress and tissue antioxidant
profiles. The study was conducted in accordance to ethical
guidelines for animal research.
Previous
published human and laboratory studies have shown GliSODin’s
effectiveness in protecting cells from oxidative stress by
activating the body’s production of its own antioxidants,
including SOD, catalase and glutathione peroxidase.
This
“internal antioxidant defense system” is necessary for the
elimination of the free radicals produced by oxidative stress,
resulting in tangible health benefits, including helping protect
cellular DNA from oxidative stress, inhibit photo-oxidative
stress in the sun-sensitive, inhibit lactic acid accumulation
under exercise, help restore normal levels of SOD, and
positively affect other significant markers of oxidative stress.
More
information on GliSODin is available at the research site
www.glisodin.org and
www.glisodininfo.com
About
GliSODin®
GliSODin is
patented and trademarked by Isocell, Paris, France.
www.GliSODin.com It is available in North America as a
nutritional raw material exclusively from PL Thomas & Co.,
Morristown, NJ. Numerous in vivo and human studies support the
use of GliSODin in nutritional applications
About PLT
PL Thomas & Co., a New Jersey-based ingredient supplier, offers
fifty years of innovation in securing reliable, high quality raw
materials for the food/functional food and nutrition industries.
1 Kick, et. al., “Effects of a cantaloupe melon
extract/wheat gliadin biopolymer during aortic cross-clamping,”
Journal Intensive Care Medicine 10.1007/s00134-006-0518-6
2Muth,
et. al. "Influence of an orally effective SOD on hyperbaric,
oxygen related cell damage,” Free Radical Research 38:9
(2004) pp. 927-932
# # #
|
